Alora vs Dotti: What to Do Now That Alora's FDA Approval Has Been Withdrawn

Alora vs Dotti: the decision, in one table

All rows checked July 10, 2026. Sources listed at the bottom of this page.

Best for you if / Not for you if

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

What we actually verified

We didn't summarize other websites. We opened the source documents.

• We read the Federal Register notice withdrawing Alora's approval (90 FR 36440, published August 4, 2025, Docket FDA-2025-N-2422), and the correction published October 3, 2025 (90 FR 48056), which changed only Zinecard's application number and did not affect Alora.
• We read Alora's final FDA-approved prescribing information, revised May 2025 before the withdrawal.
• We read Dotti's current DailyMed label, revised May 2024, packaged by Amneal Pharmaceuticals.
• We did the arithmetic ourselves and cross-checked it against Alora's own measured absorption figure. It matched.
• We checked the FDA's list of menopausal hormone therapies with updated prescribing information on July 10, 2026. No estradiol patch is on it.
• We pulled cash prices from GoodRx and SingleCare on July 10, 2026.

What we did not do: wear either patch, or run a study. We did not find a published head-to-head clinical study of Alora versus Dotti in the FDA labels or the sources we reviewed through July 10, 2026. Anyone who tells you one “works better” is giving you an opinion.

Clinical and product-spec rows in our tables come from FDA or DailyMed labeling. Approval, availability, and price rows come from separately dated regulatory and commercial checks. Ratios and delivery-per-area figures are our calculations, and we label them that way every time.

Before you change anything

Dotti's current label lists these contraindications — reasons a prescriber should not give it to you at all: undiagnosed abnormal genital bleeding; breast cancer or a history of breast cancer; estrogen-dependent cancer; active or previous deep vein thrombosis or pulmonary embolism; active or previous arterial clotting disease such as stroke or heart attack; known allergic reaction, angioedema, or hypersensitivity to Dotti; liver impairment or disease; and protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders. This is not a complete list — review the full label with your prescriber.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — before you book anything.

One small thing, before you read on

Go get your patch box. Write down three things:

1. The manufacturer (it's on the carton)
2. The full NDC number (also on the carton — a long number in three parts)
3. The strength, in mg/day

Then add the date your patch changed and the date anything about how you felt changed.

That's it. Four lines on a piece of paper. It is the single most useful thing you can bring to a prescriber, and almost nobody brings it. Everything below will make more sense once you have it in front of you.

Was Alora discontinued, or was it withdrawn by the FDA?

Both, in that order.AbbVie stopped marketing Alora, then formally asked the FDA to withdraw approval of the application. The FDA granted that request, and approval of NDA 020655 — all four strengths, plus every amendment and supplement — was withdrawn effective September 3, 2025. The withdrawal was not based on safety or effectiveness.

This distinction matters more than anything else on this page, so let's be precise about what happened.

The chronology, assembled

We put this together from four separate primary documents. As far as we could find, it has not been published in one place before.

Look at May 2025. The FDA approved an updated Alora label four months before withdrawing the drug's approval entirely. That's why a current-looking Alora label still sits on the FDA's own servers today, and it's why so many websites — and possibly your prescriber's software — still act as though Alora is a live option.

It isn't.

What “withdrawn” actually means here

The Federal Register notice is unusually plain. The applicants informed the FDA that the drugs were no longer marketed and requested withdrawal. They waived their right to a hearing. The FDA processed the request under 21 CFR 314.150(c).

Three consequences follow, and each one answers a question you probably have.

It was not a safety recall. No new risk was found. No adverse event triggered it. If you took Alora for a decade, nothing about this notice suggests you were harmed. This is the part that several 2026 articles get wrong by omission, and it's the part that matters most to your peace of mind.

New Alora cannot lawfully be distributed. The notice states that introducing these products into interstate commerce without an approved application violates federal law. So your pharmacy cannot order more.

But existing stock wasn't instantly frozen. The same notice says products in inventory on September 3, 2025 could continue to be dispensed until inventories were depleted or the product expired. Nearly two years on, the odds of unexpired Alora sitting on a shelf are slim — but “slim” is not “zero,” and you are allowed to ask. If a pharmacy says it has some, that's lawful.

Could it come back? The notice says the withdrawal is “without prejudice to refiling,” which means the legal door is not bolted shut. We have seen no announcement that AbbVie intends to walk back through it.

Is Dotti a generic of Alora, or of Vivelle-Dot?

Dotti is an ANDA product — approved through the generic pathway — and its approval references Vivelle-Dot, not Alora. Nothing was ever FDA-rated as an interchangeable substitute for Alora. That means a pharmacist swapping you into Dotti was not performing a routine Alora substitution, because no such substitution exists.

An ANDA is an Abbreviated New Drug Application: the pathway a company uses to get a generic approved by proving it delivers the same drug into the blood the same way as an already-approved reference product. It doesn't have to repeat the original trials. It has to match the original product.

Dotti's own label describes it as “the revised formulation with smaller system sizes,” shown to be bioequivalent to “the original formulation of estradiol transdermal system, used in the clinical trials.” Drugs.com's generic-availability record for Vivelle-Dot lists Dotti among its generics. The label itself never names a brand.

Alora took the other road. It held its own New Drug Application, NDA 020655, with its own clinical trials. No generic was ever approved against it.

So here's what that means for you. Whether a pharmacy may substitute one product for another depends on the therapeutic-equivalence group in the FDA's Orange Book, your state's dispensing law, what your prescriber wrote, your insurance, and what's on the shelf. A Dotti-for-Vivelle-Dot swap fits Dotti's approval relationship neatly. A change from Alora to Dotti is a different decision — a prescribing or dispensing choice someone made, not an automatic generic substitution.

If your pharmacy told you it “substituted” Dotti, go look at your last box. Read the brand name and the manufacturer. That one line on the carton tells you which conversation you're actually having.

What is physically different between Alora and Dotti?

At every matching strength, a Dotti patch covers about 21% of the skin area an Alora patch covered and holds about 41% of Alora's estradiol — while being labeled to deliver the same milligrams per day. Both are estradiol, the same hormone your ovaries made, delivered through skin. The difference lives entirely in the adhesive that holds the drug and releases it.

Here is the comparison, built from the two labels. We did not find this exact strength-by-strength table in any source we reviewed as of July 10, 2026.

Patch area and estradiol payload, side by side

That 21% holds at all four matching strengths. It isn't a rounding accident. It's two different adhesive systems hitting the same delivery target from opposite directions.

At 0.05 mg/day, Alora's active area was 18 cm² and Dotti's is 3.78 cm². Nearly five Dotti patches would fit inside the space one Alora patch used to occupy.

One correction to a claim you'll see elsewhere: Dotti is not the smallest twice-weekly estradiol patch on the market. At 0.05 mg/day, Minivelle's labeled active area is 3.30 cm² — smaller than Dotti's 3.78 cm². Dotti is dramatically smaller than Alora. It is not the smallest.

Two other real differences

Dotti has a rung Alora never had. Dotti comes in 0.0375 mg/day. Alora didn't. Dotti's label starts hot-flash treatment at 0.0375 mg/day; Alora's started at 0.05. If you're sensitive to estrogen, restarting after a break, or hunting for the lowest dose that works, that extra rung is a real advantage — and a legitimate reason a clinician might have chosen Dotti on purpose rather than by accident.

Alora could go on your hip. Dotti can't. Alora's label approved the lower abdomen, the upper quadrant of the buttock, and the outer aspect of the hip. Dotti's label approves the trunk — abdomen or buttocks — and does not list the hip. Neither goes on the breasts.

That isn't trivia. Both labels show that where you put the patch changes your blood levels. In a single-dose study of 31 women in Alora's label, the hip produced a peak estradiol level of 69 pg/mL versus 53 pg/mL on the abdomen, a difference the label calls statistically significant. In Dotti's label, the 0.1 mg/day system applied to the buttocks produced a mean peak of 145 pg/mL versus 133 pg/mL on the abdomen.

If you moved your patch to a new spot the same month you changed brands, you changed two variables at once. That's worth telling your prescriber.

Do Alora and Dotti deliver the same dose?

Both are labeled to deliver the same milligrams of estradiol per day at matching strengths, and their published blood-level figures are close. The estradiol printed on the box is the amount loaded into the adhesive — not the amount that reaches your bloodstream. A patch holding less drug is not a weaker patch.

This trips up nearly everyone, so let's slow down.

Payload is not dose

Every used patch you throw away still has estradiol in it. Sometimes most of it. The number on the label — 1.5 mg for Alora at 0.05 mg/day, 0.627 mg for Dotti at the same strength — is the payload: what sits in the adhesive on day one. The dose is what crosses your skin over the wear period. Different adhesive designs need very different payloads to release the same dose.

Do the division and the gap is startling:

At 0.05 mg/day, Alora held about 2.39 times Dotti's estradiol payload across about 4.76 times the active area.

Here's how we know the arithmetic is sound. Alora's own label reports that across 251 measured wear-occasions in 123 postmenopausal women, the average absorbed dose was 0.003 ± 0.001 mg of estradiol per cm² per day. Our calculated 0.0028 for Alora lands inside that band. The math checks itself against the manufacturer's own measurement.

What the blood-level data show, and what they don't

Both labels publish steady-state blood levels. Both also warn, in almost identical language, that you cannot compare across products this way.

Numerically close. But read that second row label carefully: those are not Dotti's numbers. They are the original formulation's numbers, printed in Dotti's label because Dotti was approved by proving bioequivalence to that formulation. This is not a head-to-head study, and it is not the evidence the FDA used to approve Dotti — that evidence was a comparison against Dotti's reference product, not against Alora.

Now read what Alora's own label says in section 12.2, and note that Dotti's label says the same thing almost word for word:

A serum concentration does not predict an individual woman's therapeutic response, nor her risk for adverse outcomes. Exposure comparisons across different estrogen products to infer efficacy or safety for the individual woman may not be valid.

Both manufacturers are telling you, in their own labels, that a population average cannot promise anything about your body. Alora's label separately notes that person-to-person variation in skin permeability runs around 20%.

That is where the published evidence stops. Nobody has studied whether a patch that concentrates its delivery into one-fifth the skin area behaves differently, person to person, than one that spreads it out. We're not being coy — that study does not exist, and you deserve to know exactly where the map ends rather than be handed a theory dressed up as a finding.

Which patch sticks better, Alora or Dotti?

The commonly quoted comparison — 97% for Alora versus 85% for Dotti — is not valid, because the two labels are counting different things.Alora's 97% figure includes patches that were partly lifting. Dotti's 85% counts only patches that stayed completely stuck. These came from separate studies of different products, so they cannot be pooled into a winner.

This is the most misread pair of numbers in the estradiol patch world. Look at what each label actually did.

Read that Alora row again. Its headline adhesion number came from women told not to bathe or swim, wearing a fake patch, in one of its four sizes — and the label openly admits the other three sizes were never studied for adhesion at all.

What we can say with confidence: the 97%-versus-85% comparison is meaningless as published. Both labels happen to report roughly 3% complete detachment, but those figures came from different studies and do not prove the two patches adhere equally in real life.

What we can't say: which one will stay on your skin. No head-to-head adhesion study exists.

What actually helps: application site, skin prep, friction from clothing, heat, sweating, and bathing all affect adhesion, and the labels don't tell us which factor wins for any individual. Both labels give the same practical instructions — press the patch down with your palm for a full 10 seconds, rotate sites with at least a week between repeats, and avoid your waistline, because tight clothing rubs patches off.

And both labels say the same thing about a patch that falls off: you can reapply the same one. If it won't stick, put a new one on a different spot and keep your original change-day schedule. Don't restart the clock.

What side effects does each label actually report?

Alora's label reports breast pain as its most common adverse reaction, rising from 8.0% on placebo to 34.8% at the 0.075 mg/day dose. Dotti's label lists headache, breast tenderness, and irregular bleeding or spotting among reactions occurring in 10% or more of patients, and reports application-site redness and irritation in 3.2% or fewer. These come from different trials with different designs, and neither label permits comparing them directly.

Alora's dose curve

From Alora's two-year bone-density trial in 355 women. This table lists only reactions occurring in more than 2% of women and more often than with the placebo patch.

The reported rate of breast pain rose across the three Alora dose groups, from 14.6% at 0.025 mg/day to 34.8% at 0.075 mg/day. If your breasts started aching after a dose increase, that is not in your head. It was the most commonly reported reaction in Alora's own trial.

The absence that tells you something about the table, not about your skin

Application-site reaction does not appear in Alora's table above. That's because it didn't clear the table's threshold: more than 2% of women and more often than placebo.

Be careful with what that does and doesn't prove. It does not identify what causes skin reactions, and it does not show that Alora and a placebo patch irritated skin identically. It tells you the reaction wasn't reported more often on the drug than on the fake patch in this trial, and so it wasn't printed. That's a fact about how adverse-reaction tables are built — and it's why reading past the headline matters.

Dotti's reported reactions

Dotti's label names headache, breast tenderness, nasopharyngitis, sinusitis, sinus headache, upper respiratory infection, back pain, depression, and irregular vaginal bleeding or spotting as reactions occurring in 10% or more of patients. Application-site redness and irritation were seen in 3.2% or fewer across treatment groups.

Do not put 34.8% and 3.2% in the same sentence. They measure different reactions, in different trials, over different durations. Both labels state outright that adverse reaction rates from one drug's trials cannot be compared to another's. We show you both because you deserve to see what each company actually measured — not because one wins.

Why did my symptoms come back after my pharmacy switched me to Dotti?

Dotti's FDA label states plainly that no clinical trials were conducted with Dotti. Its approval came through the generic pathway, by proving bioequivalence to the original formulation, whose trial data appear in Dotti's label. On Drugs.com, Dotti carries an average patient rating of 3.9 out of 10 across 59 reviews, with 64% of reviewers reporting a negative experience— checked July 10, 2026. Generic estradiol patches average 4.7 out of 10 across 183 reviews. Climara averages 6.3 across 63.

We're not going to soften that. It's the most important paragraph on this page.

The honest version

What's true, and uncomfortable: no trial was ever run on this exact patch. Alora had two of its own — a 12-week placebo-controlled trial in 268 women showing 0.05 and 0.1 mg/day reduced the frequency and severity of moderate-to-severe hot flashes more than placebo, and a two-year bone-density trial in 355 women in which lumbar spine bone density rose across the Alora dose groups while it fell in the placebo group. If a product with its own trial file is what you need to feel safe, Alora had one — and Alora's approval is withdrawn. You cannot have it. That door is closed.

Here's what the generic pathway actually buys you. Because Dotti had to demonstrate it delivers estradiol into the blood the same way as the formulation that ran those trials, the evidence behind the molecule and the transdermal route still stands behind Dotti — and its label reproduces that trial data in full. And because it went through that pathway, a pharmacist is permitted to dispense it as a substitute within its equivalence group. That is precisely why it is the patch you can actually get in 2026. Alora's trial file is worth nothing to you if you can't buy Alora.

What bioequivalence never promised is that your skin behaves like the study average.

If you want a patch with its own product-specific trial record, that's a real preference, and Dotti isn't it. Look at Climara or Minivelle with your prescriber, or read our once-weekly vs twice-weekly estradiol patch comparison. We'd rather point you somewhere useful than talk you into something.

How to read a 3.9 out of 10

Several of Dotti's most prominent negative reviews describe the same sequence: an unwanted manufacturer change, then symptoms returning, then relief on switching back. That is a recurring theme in the reviews — not a measured rate, and not proof that Dotti caused anything.

These are voluntary, self-selected online reviews. They cannot establish comparative effectiveness, how often side effects occur, or how likely you are to do well or badly. Nobody writes a review about the month nothing happened. Read a 3.9 as a map of substitution distress, not as a verdict on the medicine.

These are individual, unverified consumer reviews from a public pharmacy review page. They cannot establish safety, effectiveness, or cause.

“All generics are not equal!!!”
— Drugs.com reviewer, October 2022

Her frustration is legitimate. The patches genuinely are not identical objects — the 21% figure above proves that. What her experience cannot tell us, and what no review can, is whether the difference she felt lived in the patch, in her skin, in the timing, or somewhere else entirely.

So here's the useful thing to do with all of it. A change in your symptoms after a switch is not proof of anything, and it is not nothing. It is a reason to write down the dates and call your prescriber — not to change your dose, stop treatment, or ride it out alone while you decide whether you're imagining it.

You are not being difficult. You are being specific. That's what a prescriber can actually work with.

Affiliate disclosure: The HRT Index may earn a commission if you book through the provider links below, at no extra cost to you. The providers did not review or approve this article, and no company paid to be included.

Does this sound like your situation?

The thing you need isn't a new brand. It's a clinician who will write a manufacturer on the prescription and talk through what changed.

How do I get my pharmacy to give me a specific estradiol patch manufacturer?

A prescriber can prohibit substitution — commonly recorded as “dispense as written,” or DAW-1 — and name a preferred product or its full NDC number.Whether the pharmacy can then fill it depends on the prescription being valid, that exact product being available, your state's dispensing rules, and your insurance. If it can't be filled, the pharmacy or prescriber will need to discuss an alternative.

Most women never learn this option exists. It is not a guarantee. It is a lever, and it's yours to ask for.

Use the full NDC, not a prefix

Every drug carton carries an NDC — National Drug Code — printed as three numbers separated by dashes. The first segment is the labeler code, which identifies the company that put its name on the package. That's a manufacturer, repackager, or relabeler. On its own, it does not tell anyone your strength or package size.

So don't say “the one made by Amneal.” Read the full NDC off your carton and give all three parts. Amneal's five Dotti listings on DailyMed are 65162-989, 65162-992, 65162-993, 65162-995, and 65162-997, each supplied in 4-count and 8-count packages. Yours is on the box. Copy it exactly. (You may see it written with an extra zero — 65162-0992-08 — which is the same code in billing format.)

Say this to your prescriber

“The patch I've done well on is labeled by ______, at ______ mg/day, NDC ______. Could you decide whether to prescribe that exact product, and if it's appropriate, mark substitution as not permitted and include the full NDC? If it's unavailable or not covered, what's the backup plan?”

Say this to your pharmacist

“Which manufacturer are you dispensing today? Is that the same one as last time? If it's different, can you order the one I had, and how long would that take? Can your system record a manufacturer preference on my profile?”

Some pharmacy systems can store that preference and some can't. Ask anyway. Almost no one does.

Bring the paper

You wrote it down at the top of this page: manufacturer, full NDC, strength, and the dates. Bring that. A prescriber facing “I think it stopped working” and a prescriber facing four dated lines are two different prescribers.

Which Dotti strengths are back-ordered right now?

ASHP's estradiol transdermal system shortage bulletin, last updated July 1, 2026, lists Dotti 0.025, 0.05, and 0.075 mg/day eight-count cartons on back order with no estimated release date. Dotti 0.0375 and 0.1 mg/day are listed as available.A national listing does not guarantee your local pharmacy's shelf — call before you drive.

Note which three those are. 0.05 mg/day is the most commonly dispensed twice-weekly strength, and it's the one on back order. If you've spent six weeks confused about why your refill keeps failing, that's why.

Why the FDA and ASHP disagree

The FDA has not listed any estradiol patch on its drug shortage database. It told CNBC in June 2026 that all six manufacturers are producing at full capacity. Meanwhile ASHP — the American Society of Health-System Pharmacists, which collects reports from pharmacists and patients — began listing estrogen patches in January 2026. By March, AARP counted 10 patch products on ASHP's bulletin. By May, journalists counted 14 brands or doses.

Both can be right, and understanding why saves you a phone call.

An FDA shortage listing generally requires a manufacturer to report a supply disruption. If every plant is running flat out and demand simply exceeds output, there's no disruption to report — and the shelf is empty anyway. ASHP's list is populated by the people standing in front of that shelf.

Why patches specifically? Manufacturers told NPR and CNBC that transdermal patches are complex to make: the drug has to be dissolved into an adhesive and coated to a precise thickness. Amneal confirmed to NPR a significant increase in demand following the FDA's removal of boxed warnings from other hormone therapy products. Prescriptions for estrogen patches rose 162% over two years, according to HealthVerity data reported by CNBC.

Practical move: ask your pharmacy and your insurer how early your plan allows a refill, and whether a shortage, travel, or continuity-of-therapy override is available. Refill-too-soon rules vary by plan, by drug, and by state. Don't assume you can simply refill a week early — ask, then plan around the answer.

Does Dotti still have a black box warning?

Yes. On February 12, 2026, the FDA approved labeling changes removing cardiovascular disease, breast cancer, and probable dementia from the boxed warning — but only for six products: Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva. No estradiol patch is among them.Dotti's current label, revised May 2024, carries the full boxed warning. So did Alora's final label.

A boxed warning — the “black box” — is the strongest warning the FDA puts on a prescription label.

The timeline, plainly:

• November 10, 2025: HHS and the FDA announce they will begin removing the broad boxed warnings from menopausal hormone therapy products, citing a re-analysis of Women's Health Initiative data in younger women.
• February 12, 2026: The FDA approves the first batch of labeling changes. Six products. The agency has said 29 companies submitted proposals.
• July 10, 2026: We checked the FDA's own published list. It still names those six. No patch has been added.

The endometrial cancer boxed warning stays on systemic estrogen-alone products regardless. The FDA's labeling initiative retained it.

So what should you do with the box on your Dotti carton? Read it. Dotti's current boxed warning remains in effect unless and until the FDA approves revised labeling for Dotti. The changes approved for six other products do not amend Dotti's label, and you should not treat the warning as though it has been lifted for your patch. It hasn't.

We re-check this monthly. If a patch appears on the FDA's list, this section changes and the date at the top of this page changes with it.

How much does Dotti cost without insurance?

On July 10, 2026, GoodRx displayed a lowest coupon price of $38.07 for eight Dotti 0.05 mg/day patches, against a modeled retail estimate of $123.58; GoodRx stamped its coupon prices as updated July 8, 2026. SingleCare displayed $51.57 with its membership terms, against a modeled retail estimate of $190.93.Generic estradiol patches ran roughly $36 to $53 for eight patches. Alora has no reliable current price, because it isn't sold.

Three things in that paragraph are worth pausing on.

The brand name may not be costing you much. On the same GoodRx surface we checked, Dotti's lowest coupon price was $38.07 and generic estradiol patch's lowest was $36.23 — a difference of about two dollars a month. Coupon prices move by pharmacy and ZIP code, so check both for your own strength and location. But if you've been avoiding Dotti because it sounds expensive, that assumption may be costing you nothing and gaining you nothing. Price is probably not the reason to choose or refuse it.

“Average retail price” is a model, not a receipt. Two coupon sites showed retail estimates for the identical carton that differ by more than sixty dollars. Neither is a posted price. Treat every retail estimate you read — including in our table — as directional only. Your actual price has to be confirmed at the counter. We won't guess it for you.

Coverage is plan-specific, not category-specific. Medicare Part D coverage varies by plan and by product. Look up your exact Dotti or estradiol-patch NDC in your plan's current formulary and check the tier, prior-authorization status, quantity limit, and preferred pharmacy before you count on coverage. Ask your pharmacy whether any current Dotti savings program applies — we did not verify one.

What if your only symptoms are vaginal dryness, painful sex, or urinary discomfort?

If vulvar and vaginal symptoms are your entire complaint, a whole-body estradiol patch may not be the first thing to ask about. Both the Alora and Dotti labels carry the same Limitation of Use: when prescribing solely for moderate to severe symptoms of vulvar and vaginal atrophy, first consider the use of topical vaginal products. That instruction is printed in the FDA-approved prescribing information for both.

Read that again, because it's coming from the drug companies themselves, in the labels the FDA approved.

A patch sends estradiol through your whole body. Low-dose vaginal estrogen — creams, tablets, inserts, or a ring — is designed to treat local genitourinary symptoms, and systemic absorption is generally minimal at standard low doses, though absorption varies by product and dose. If hot flashes, night sweats, and sleep aren't your problem, a patch may be more medicine than your problem requires.

Both labels carry a second Limitation of Use worth knowing: when prescribing solely to prevent postmenopausal osteoporosis, first consider non-estrogen medications, and consider estrogen only for women at significant risk.

Do I need progesterone with Dotti or another estradiol patch?

If you have a uterus and use systemic estrogen, ask how your endometrium — the lining of your uterus — will be protected. Estrogen used without adequate protection increases endometrial cancer risk.Dotti's label instructs that when estrogen is prescribed for a postmenopausal woman with a uterus, a prescriber should generally consider adding a progestogen. A woman without a uterus generally doesn't need one, though the label notes an exception for a history of endometriosis.

This is not a footnote. It is the one boxed warning the FDA specifically did not remove in 2026.

Progestogen is the umbrella term for progesterone and the synthetic progestins. Adding one is the standard way to protect the uterine lining from unopposed estrogen. The exact drug, dose, and schedule are an individualized prescription, and there are other endometrial-protection strategies a clinician may use. What matters is that someone has a plan and has told you what it is.

If a prescriber hands you an estradiol patch and never asks whether you have a uterus, that is a reason to ask a second question.

One more number to carry into that conversation. Alora's own trial data showed reported breast pain rising from 8.0% on placebo to 34.8% at 0.075 mg/day. Dose matters. Both labels instruct prescribers to use the lowest effective dose for the shortest duration consistent with your goals, and Dotti's label says to attempt to taper or discontinue at three-to-six-month intervals. Ask when your next reassessment is scheduled.

Report any unexpected vaginal bleeding to your clinician promptly. Both labels are unambiguous about this.

What are the alternatives if you can't get your Dotti strength?

Don't guess at a substitute, and don't cut or alter a patch unless your prescriber or pharmacist confirms that specific product can be used that way. Ask which FDA-approved options fit your dose and route, and whether your prescription allows substitution. Availability shifts week to week and pharmacy to pharmacy.

Options to raise with a clinician, not to switch to on your own:

How The HRT Index verified this comparison

This page was built under The HRT Index Verification Standard — our documented process: read every published price, separate FDA-approved from compounded, verify availability and insurance, and re-check on a fixed schedule.

We sort every claim into one of three buckets, and we label them:

1. Medical and regulatory facts — approval status, boxed warnings, dosing, patch dimensions, adhesion data, adverse reaction rates, contraindications. Sourced only to the Federal Register, FDA prescribing information, DailyMed, and FDA announcements.
2. Commercial facts — prices, availability, back-order status. Dated to the day we checked and traced to a named source.
3. Our calculations and editorial conclusions — the 21% ratio, the payload figures, the delivery-per-area column, our reading of the review data. Labeled as ours every time, never dressed up as findings.

What is still open, and we're telling you rather than hiding it

• ASHP's bulletin blocks automated checking and updates frequently. Our figures reflect its July 1, 2026 update.
• We have not confirmed the exact date of Alora's 2021 discontinuation report against an FDA source. The 2025 withdrawal is confirmed at the Federal Register.
• Dotti's label does not name its reference brand. We rely on Drugs.com's Vivelle-Dot generic-availability record for that relationship.
• Patient review figures move. Ours were checked July 10, 2026.

Refresh schedule: shortage status and the FDA labeling list, monthly. Prices, monthly. Product labels and patient rating data, quarterly. The “Last verified” date at the top changes only when we actually re-check. If you find something wrong here, tell us and we'll fix it and log the change.

Who is not on this page, and why

We have affiliate relationships with Winona and Inner Balance (Oestra). Neither appears as a recommendation here.

Both are compounded providers. This is a brand-name, FDA-approved transdermal estradiol page, and pointing a woman who just lost her FDA-approved patch toward a compounded-first provider would be the most trust-destroying move available on this site. Under our FDA-Approved Override rule, compounded providers are never featured as recommendations on FDA-approved brand pages — regardless of what we're paid.

Affiliate disclosure: The HRT Index may earn a commission when you book through links on this page. It doesn't change what we found in the labels, and it didn't change what we wrote.

The HRT Index evaluates providers on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, and access.

Where this leaves you

Alora is not coming back to your pharmacy, and nobody found anything wrong with it. AbbVie stopped making it and the FDA closed the file.

Dotti is a real, FDA-approved medicine. It is about a fifth the size of what you used to wear — not because it's weaker, but because it's built differently. Your strength may or may not be on the shelf this month, and that has nothing to do with you.

If your patch is working, you're fine. If it isn't, you now have four lines on a piece of paper and three words most women never hear: dispense as written.

That's not being difficult. That's being specific. Go be specific.